A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
A phase 3 trial testing JNJ-87189401 in prostate cancer, now recruiting.
Overview
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT07164443, led by Janssen Research & Development, and recruiting when checked on 2026-09-11. Official title: A Phase 3 Randomised, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer. Planned enrolment is 1203 participants (estimated). The study started in 2025-09-02 and primary completion is expected in 2028-08-18. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Shares Prostate cancer and the tag ctgov-ingest.